Hims & Hers Previews Peptides+, Citing the HHS Draft Peptide Policy

One day after the Department of Health and Human Services announced a draft peptide compounding policy, a major national telehealth company previewed a peptide specialty, with its release framed as a response to the announcement. Hims & Hers co-founder and CEO Andrew Dudum previewed a new Peptides+ specialty in an October 29 company release, naming sermorelin, glutathione, B12, NAD+ and L-carnitine as planned offerings, "with BPC-157 and TB-500 to follow when allowable." [1]

What the company announced

The release describes Peptides+ as "a clinically guided protocol that targets health and wellness at a cellular level," with personalized plans "prescribed and delivered by independent providers, treatments supplied by licensed pharmacies." It is a preview with a waitlist, not a launched product. [1]

Dudum wrote that the company has "spent years building the infrastructure we need in our very own U.S.-based peptide manufacturing facility," developing dosing protocols with clinical experts. He was also direct about the evidence: "Most of what we know about these compounds is still early, with limited published studies," the release says, adding that the company is "focused on entering this specialty the right way, not the fastest." [1]

The two named peptides from the federal policy's six-substance group, BPC-157 and TB-500, come last in the company's own ordering and carry the condition "when allowable." The release does not mention the other four substances in the policy (epitalon, KPV, MOTS-c and semax). [1][2]

What the policy does and does not allow

The policy the company is pointing at is a draft enforcement discretion policy HHS announced the day before the release; the notice of availability was published in the Federal Register October 30, at 91 FR 68526. The policy says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians compounding the six peptides for individual patients, provided ten conditions are met, while the 503A bulks list goes through rulemaking. [2][3]

The notice is explicit about what the policy is not. It is a draft, it "does not establish any rights for any person and is not binding on HHS or the public," and compounded drugs are not FDA-approved. It covers 503A compounding for individual prescriptions, not 503B outsourcing facilities making batches. Comments on docket HHS-OASH-2026-0496 close at 11:59 PM Eastern on November 13. [2][3]

The company's own risk factors make the same point in securities language: its plans are subject to "changes in HHS's draft interim policy or the final outcome of rulemaking." [1]

Why telehealth can move this fast

The GLP-1 years built the machinery. Online prescribing, partnered licensed pharmacies and home delivery became a mainstream channel during the semaglutide and tirzepatide shortages; in a KFF poll fielded in late October 2025, 17% of people who had taken a GLP-1 drug said they got it from an online provider or website. [6]

That channel's original product class has narrowed. FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, and its April 1, 2026 reminder states that neither drug appears on the 503B bulks list or the shortage list. [4] Peptide Policy Watch's reading of the timing: the draft policy, if it becomes final, gives the existing telehealth infrastructure somewhere to go. [5]

The limits the company itself names

The release is a plan, and it labels its own unknowns. Beyond the draft-policy caveat, the company's cautionary note lists "the limited clinical data available on peptide therapies, including their safety and efficacy and the possibility of side effects that are not yet known," its reliance on independent providers and licensed pharmacies, and the timing and feasibility of expanded access to BPC-157 and TB-500. [1]

The next regulatory marker the release itself points to is FDA's next Pharmacy Compounding Advisory Committee meeting, which is expected to weigh five more peptides for compounding. [1][5]

The biggest signal in the announcement is not the waitlist. It is that a publicly traded telehealth company now treats a draft peptide policy as a product roadmap, with the caveats printed in the same release.

What it means for a clinic: A major national telehealth brand is preparing to sell into the peptide category, and it is framing the draft policy as, in Dudum's words, "meaningful progress toward a regulated, safer pathway to care." The draft policy is not a final policy or FDA approval; it "does not establish any rights for any person and is not binding on HHS or the public," and the company's own timeline for BPC-157 and TB-500 is "when allowable." The draft is open for public comment through November 13, and the notice sets no date for a final version.